Hansa Biopharma half year report 2023
· Solid product sales in Q2 2023 · Collaboration announced in gene therapy with Genethon in Crigler-Najjar syndrome · New Eurotransplant desensitization program implemented in June · First patient treated in new investigator-initiated Phase 2 study in ANCA-associated vasculitisLund, Sweden, July 20, 2023, Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January to June 2023. Highlights for the second quarter of 2023 · Total Q2 revenue of SEK 36.7m consisting of SEK